Drugs / MIZACORAT
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02760316 | May 2016 → Sep 2017 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02512575 | Nov 2015 → Sep 2016 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04556760 | Nov 2020 → Jun 2021 | type 2 diabetes mellitus | AstraZeneca | Completed | Mixed |
| Phase 2 | NCT03368235 | Jan 2018 → Nov 2019 | rheumatoid arthritis | AstraZeneca | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIZACORAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4207852 ↗ |
| Known as | AZD9567 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02512575 ↗ |
| Modality | Small molecule | — CHEMBL4207852 ↗ |
| Route | Oral | “single oral doses of AZD9567 2 mg, 10 mg, 20 mg, 40 mg, 80 mg, 100 mg, 125 mg, or 155 mg” PMID 38258274 ↗ Dec 2019 |